Cero Therapeutics Holdings, Inc. (CERO): R&D Expense

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest R&D Expense is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$5.29M
Year ended 2023-12-31
Period endedR&D ExpenseChange YoYSource filing
2023-12-31$5.29Mn/a2025-04-15, From 2023-01-01